Roche's Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer

Roche today announced that the European Commission (EC) has approved the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news